Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.92 NOK | +3.94% |
|
+11.86% | +62.96% |
05-30 | Transcript : Lytix Biopharma AS, Q1 2024 Earnings Call, May 30, 2024 | |
05-30 | Lytix Biopharma AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+62.96% | 36.76M | - | ||
+40.80% | 53.67B | B- | ||
+35.79% | 38.86B | A | ||
-8.05% | 38.76B | B | ||
-8.98% | 27.27B | C | ||
+10.69% | 25.91B | B- | ||
-16.21% | 20.29B | B | ||
+31.00% | 12.78B | B+ | ||
+28.51% | 12.18B | C+ | ||
-1.67% | 11.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LYTIX Stock
- Ratings Lytix Biopharma